Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?
- PMID: 35854417
- PMCID: PMC9552211
- DOI: 10.1093/jnci/djac113
Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?
Comment on
-
Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.J Natl Cancer Inst. 2022 Oct 6;114(10):1347-1354. doi: 10.1093/jnci/djac112. J Natl Cancer Inst. 2022. PMID: 35854422 Free PMC article.
References
-
- Arimidex T, Buzdar A, Howell A, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633-643. - PubMed
-
- Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22(21):4261-4271. - PubMed
-
- Sussman TA, Kruse ML, Thacker HL, Abraham J. Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy. J Oncol Pract. 2019;15(7):363-370. - PubMed
-
- Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121-134. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical